UY34721A - Anticuerpos anti-hla-b*27 y usos de éstos. - Google Patents
Anticuerpos anti-hla-b*27 y usos de éstos.Info
- Publication number
- UY34721A UY34721A UY0001034721A UY34721A UY34721A UY 34721 A UY34721 A UY 34721A UY 0001034721 A UY0001034721 A UY 0001034721A UY 34721 A UY34721 A UY 34721A UY 34721 A UY34721 A UY 34721A
- Authority
- UY
- Uruguay
- Prior art keywords
- hla
- antibodies
- escanear
- figuras
- escanear figuras
- Prior art date
Links
- 241000950314 Figura Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618969P | 2012-04-02 | 2012-04-02 | |
| US201361778703P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34721A true UY34721A (es) | 2013-10-31 |
Family
ID=48093122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034721A UY34721A (es) | 2012-04-02 | 2013-04-02 | Anticuerpos anti-hla-b*27 y usos de éstos. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9790273B2 (enExample) |
| EP (1) | EP2834272B1 (enExample) |
| JP (1) | JP6320993B2 (enExample) |
| KR (1) | KR20150003256A (enExample) |
| CN (1) | CN104169302A (enExample) |
| AR (1) | AR090585A1 (enExample) |
| AU (1) | AU2013243644C1 (enExample) |
| BR (1) | BR112014024622A2 (enExample) |
| CA (1) | CA2868907C (enExample) |
| CL (1) | CL2014002631A1 (enExample) |
| CO (1) | CO7121320A2 (enExample) |
| EA (1) | EA201491827A1 (enExample) |
| HK (1) | HK1207092A1 (enExample) |
| IL (2) | IL234707A0 (enExample) |
| MX (1) | MX365690B (enExample) |
| MY (1) | MY171180A (enExample) |
| NZ (1) | NZ700650A (enExample) |
| PH (1) | PH12014502184A1 (enExample) |
| SG (2) | SG11201405759UA (enExample) |
| TW (1) | TWI619729B (enExample) |
| UY (1) | UY34721A (enExample) |
| WO (1) | WO2013152001A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| EP4011913A1 (en) | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| CN104080909A (zh) | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN116376983A (zh) | 2012-07-27 | 2023-07-04 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| JP6501521B2 (ja) | 2012-08-24 | 2019-04-17 | 中外製薬株式会社 | ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| KR102249779B1 (ko) | 2012-12-27 | 2021-05-07 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| TWI617580B (zh) * | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| EP3253407B1 (en) * | 2015-02-04 | 2020-04-22 | Universität Zürich | Use of hla-b27 homodimers for cancer treatment |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| EP3341738A4 (en) | 2015-08-24 | 2019-02-27 | University of Cincinnati | METHOD AND COMPOSITIONS FOR DETECTING FC RECEPTOR BINDING ACTIVITY OF ANTIBODIES |
| EP3347045A4 (en) | 2015-09-10 | 2019-08-28 | City of Hope | MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR |
| WO2017104783A1 (en) * | 2015-12-18 | 2017-06-22 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| IL259256B2 (en) * | 2015-12-18 | 2023-02-01 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| WO2017153438A1 (en) | 2016-03-08 | 2017-09-14 | Universität Zürich | Hla-b57 open conformers |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| CA3031605A1 (en) | 2016-08-10 | 2018-02-15 | Universitat Zurich | Mhc class ia open conformers |
| US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| US20200114022A1 (en) * | 2017-03-31 | 2020-04-16 | Alma Bio Therapeutics | Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| EP3710589A4 (en) | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| CN108486226B (zh) * | 2018-04-01 | 2022-04-12 | 广东辉锦创兴生物医学科技有限公司 | Hla-b27等位基因的检测试剂盒及其应用 |
| SG10202106830VA (en) | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
| EP3941489A4 (en) * | 2019-03-21 | 2022-12-28 | Gamida-Cell Ltd. | EXTENDED NK CELL FRACTIONS SUITABLE FOR POLYTHERAPY TRANSPLANTATION |
| CA3137649A1 (en) | 2019-05-15 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| CN111175490A (zh) * | 2020-01-19 | 2020-05-19 | 泛肽生物科技(浙江)有限公司 | 一种定性检测hla-b27的试剂盒及其检测方法 |
| WO2022216832A1 (en) * | 2021-04-07 | 2022-10-13 | Regeneron Pharmaceuticals, Inc. | A composition for use in treating mhc-1-opathies |
| US12157891B2 (en) * | 2021-10-14 | 2024-12-03 | Regeneron Pharmaceuticals, Inc. | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors |
| WO2023220263A1 (en) * | 2022-05-13 | 2023-11-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for modulating tcr |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340610C (en) * | 1985-08-16 | 1999-06-29 | Karen A. Nelson | Monoclonal antibody to polymorphic hla determinant-b27 |
| US5369010A (en) | 1985-08-16 | 1994-11-29 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant -B27 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| US20130315933A1 (en) | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
-
2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/zh not_active IP Right Cessation
- 2013-04-02 EA EA201491827A patent/EA201491827A1/ru unknown
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/zh active Pending
- 2013-04-02 MX MX2014011898A patent/MX365690B/es active IP Right Grant
- 2013-04-02 CA CA2868907A patent/CA2868907C/en active Active
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/ja active Active
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/en active Active
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/ko not_active Withdrawn
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/pt not_active IP Right Cessation
- 2013-04-02 UY UY0001034721A patent/UY34721A/es not_active Application Discontinuation
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 HK HK15107698.3A patent/HK1207092A1/xx unknown
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/en not_active Ceased
- 2013-04-02 US US13/855,448 patent/US9790273B2/en not_active Expired - Fee Related
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en not_active Ceased
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-03 AR ARP130101081A patent/AR090585A1/es unknown
-
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/es unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/es unknown
-
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014024622A2 (pt) | 2017-08-08 |
| CA2868907C (en) | 2022-01-04 |
| WO2013152001A2 (en) | 2013-10-10 |
| US9790273B2 (en) | 2017-10-17 |
| IL234707A0 (en) | 2014-11-30 |
| PH12014502184A1 (en) | 2014-12-10 |
| US20130259876A1 (en) | 2013-10-03 |
| KR20150003256A (ko) | 2015-01-08 |
| EA201491827A1 (ru) | 2015-03-31 |
| MY171180A (en) | 2019-09-30 |
| EP2834272B1 (en) | 2020-06-24 |
| NZ700650A (en) | 2017-02-24 |
| EP2834272A2 (en) | 2015-02-11 |
| CL2014002631A1 (es) | 2015-01-16 |
| AU2013243644C1 (en) | 2018-05-10 |
| CA2868907A1 (en) | 2013-10-10 |
| JP6320993B2 (ja) | 2018-05-09 |
| IL256716A (en) | 2018-03-29 |
| WO2013152001A3 (en) | 2013-12-27 |
| CO7121320A2 (es) | 2014-11-20 |
| AU2013243644B2 (en) | 2018-02-08 |
| AU2013243644A1 (en) | 2014-10-23 |
| TWI619729B (zh) | 2018-04-01 |
| SG11201405759UA (en) | 2014-11-27 |
| MX365690B (es) | 2019-06-11 |
| CN104169302A (zh) | 2014-11-26 |
| HK1207092A1 (en) | 2016-01-22 |
| TW201343675A (zh) | 2013-11-01 |
| AR090585A1 (es) | 2014-11-26 |
| MX2014011898A (es) | 2014-11-12 |
| JP2015514110A (ja) | 2015-05-18 |
| SG10201608136SA (en) | 2016-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
| UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
| UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
| UY34557A (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
| UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| UY34556A (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| UY34587A (es) | Formulaciones estabilizadas que contienen anticuerpos antiang2 | |
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| TWD180147S (zh) | 淨水器 | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| PH12015501954A1 (en) | Anti-b7-h4 antibodies and immunoconjugates | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| EA201691214A1 (ru) | Антитела к cd33 и иммуноконъюгаты | |
| UY34875A (es) | Purificación de partículas tipo virus | |
| EP3063691A4 (en) | DYNAMIC DE-IDENTIFICATION AND ANONYMITY | |
| UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
| UY34271A (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| UY34603A (es) | Anticuerpos anti-asic-1 y usos de los mismos | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
| UY34582A (es) | Anticuerpos anti-cxcr3 | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| EP2864479A4 (en) | MODULATION OF THE UBE3A ATS EXPRESSION | |
| UY34674A (es) | Cepa de flavobacterium plaguicida y composiciones bioactivas, metabolitos y usos | |
| MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20210528 |